ArticleAmerican journal of translational research2023
Xiaoaiping improves the general state of rats with malignant ascites secondary to gastric cancer by blocking the TGF-β1 signaling pathway.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Feasibility of vinegar processing of toxic herbs in Shi-Zao-Tang: toxicity reduction, efficacy preservation in malignant ascites rats and underlying pharmacodynamic mechanisms.Chinese medicine · 2025Article
- Integrating Chinese medicine into mainstream cancer therapies: a promising future.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of Xiaoaiping on the general state of rats with malignant ascites secondary to gastric cancer by blocking the transforming growth factor-β1 (TGF-β1) signaling pathway.
methodsFifty healthy Wistar rats were randomly divided into 5 groups, with 10 rats in each group. After successful modeling, 0.2 g/(20 g∙d), 0.4 g/(20 g∙d) and 0.8 g/(20 g∙d) of Xiaoaiping injections were administrated at the low dose group (LDG), medium dose group (MDG) and high dose group (HDG), respectively. The model group (MG) was injected intraperitoneally with the same amount of sterile normal saline for 8 d. Rats in the control group (CG) were healthy without any treatment. The general states (mental state, dietary habits, reactions and body shape) of rats in each group were observed. The abdominal circumference, platelet (PLT) count, white blood cell (WBC) count, serum ferritin (SF), ascites volume, cell survival rate, and expression levels of TGF-β1 signaling pathway (TGF-β1, Smad2) were compared among the groups.
resultsPLT and WBC counts in the MG were lower than those in the CG. Ascites volume, tumor cell survival rate, and SF in the MG were higher than those in the LDG, MDG and HDG (
conclusionXiaoaiping could significantly reduce the ascites volume in rats with gastric cancer, inhibit the production of tumor cells in the abdominal cavity, and improve the general state of rats in a dose-dependent manner. The mechanism may be related to the down-regulation of the mRNA level of TGF-β1 and Smad2.
Indexed as
Identifiers
36777819PMC9908485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.